A certain type of drug called pan-PPAR agonists might help improve liver health and blood sugar control in adults with fatty liver disease—working on both problems at once.

What we've found so far is that the evidence we've reviewed leans toward pan-PPAR agonists having a potential role in supporting liver function and glucose metabolism in adults with MASLD [1]. Our analysis of the available research shows this effect may occur because these drugs appear to act on multiple pathways involved in both liver health and blood sugar control [1]. We looked at one key assertion from the data, which indicates that pan-PPAR agonists might help improve both liver health and blood sugar regulation in adults with MASLD [1]. This single assertion is supported by 49.0 studies or analytical points, with no studies or points refuting it in our review [1]. While the number of supporting data points is high, we note that this is based on a single assertion, meaning the breadth of distinct claims reviewed is narrow so far. Because of this, our current analysis shows a strong signal, but we can’t yet determine how consistent or broad this effect may be across different populations or drug formulations. We do not yet have enough evidence to say how large the improvements are, how long they last, or whether all people with MASLD would experience similar effects. Also, we have not reviewed any direct claims about side effects, long-term safety, or comparisons to other treatments in this analysis. Our current understanding is limited to what has been submitted and coded so far. As more assertions and studies become available, our analysis may change. Practical takeaway: Early evidence we’ve reviewed suggests these drugs might help with both fatty liver and blood sugar, but it’s too soon to say for sure how well they work or who might benefit most.